docetaxel / Generic mfg. - LARVOL DELTA

Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer. (PubMed, J Genet Eng Biotechnol) - "Our findings underscore the prognostic value of the identified genes and the immunosuppressive TME in TP53-mutant breast cancer. The identification of drug candidates with strong binding affinities to key proteins provides promising avenues for targeted therapy in this high-risk patient population."

Journal • Breast Cancer • Oncology • Solid Tumor • AGR3 • CA9 • CTSC • ER • FGFR4 • PSAT1 • S100P • TFF1 • TP53

Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis. (PubMed, Eur Urol Focus) - "HRQoL outcomes differ across treatment strategies for mHSPC. At 12 mo, ADT + abiraterone yielded the most favourable HRQoL profile."

HEOR • Journal • Retrospective data • Review • Fatigue • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Pain • Prostate Cancer • Solid Tumor

A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) (clinicaltrials.gov) - P1/2 | N=649 | Recruiting | Sponsor: Amgen | Trial completion date: Nov 2028 ➔ Jun 2028 | Trial primary completion date: Dec 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Brain Cancer • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CDKN2A • MTAP

When supportive care backfires: G-CSF induced aortitis unmasked during routine adjuvant chemotherapy (ASH 2025) - "After shared decision-making, patient began monthly adjuvant docetaxel/cyclophosphamide (TC) chemotherapy with G-CSF (Neulasta) support...The patient improved dramatically with Prednisone 60mg once while hospitalized and discharged with a prolonged Prednisone taper... This case highlights how early recognition of rare treatment-related toxicities, even those tied to supportive agents like G-CSF can change the clinical trajectory and spare patients from unnecessary testing or prolonged hospitalization. Embedding red-flag symptom pathways into triage protocols, especially in high-volume cancer centers, is a practical and scalable way to protect care quality. When multidisciplinary teams are empowered with education and diagnostic curiosity, even rare complications don't stand a chance of being missed."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Infectious Disease • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Vasculitis • ER • HER-2 • PGR

Total Neoadjuvant Chemotherapy Followed by Laparoscopic Radical Gastrectomy Versus Neoadjuvant Chemotherapy for Clinical Stage T4a-bN + M0 Proximal Gastric Cancer: A Single-Center Retrospective Data Analysis. (PubMed, Gastroenterol Res Pract) - "Retrospective analysis was conducted on the clinical data of patients diagnosed with proximal LAGC who underwent perioperative docetaxel, oxaliplatin, and fluorouracil (FLOT) chemotherapy followed by laparoscopic radical gastrectomy at Longyan First Hospital affiliated with Fujian Medical University. The TNT approach for LAGC had the potential to enhance tumor regression and increase the completion rate of chemotherapy. This strategy demonstrated a positive trend in long-term outcomes and introduced a novel treatment model."

Journal • Retrospective data • Gastric Cancer • Oncology • Solid Tumor

Exploration of the efficacy of nimotuzumab combined with induction chemotherapy in locally advanced nasopharyngeal carcinoma: A multicenter, prospective phase III study (ESMO Asia 2025) - "This study aims to explore the efficacy and safety of nimotuzumab combined with induction chemotherapy in the treatment of LANPC. All patients received induction chemotherapy (docetaxel 75mg/m2 or gemcitabine 1000 mg/m2, iv, d1; cisplatin 25 mg/ m2 iv, d1-3, Q3W) combined with CCRT (cisplatin: 25 mg/m2, iv, d1-3, Q3W; IMRT/VMAT: d1-5, 5 fractions for a week). Nimotuzumab during the induction period achieved better ORR and had lower side effects caused by radiotherapy."

Clinical • Metastases • P3 data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Neoadjuvant HLX11 versus European Union (EU)-sourced pertuzumab in human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-negative early or locally advanced, breast cancer (BC): A double-blind, randomised phase III equivalence study (ESMO Asia 2025) - P3 | "Enrolled patients were randomised 1:1 to receive 4 cycles of intravenous (IV) HLX11 (HLX11 arm) or reference pertuzumab (EU-pertuzumab arm) plus trastuzumab and docetaxel every 3 weeks (Q3W). HLX11 showed equivalent efficacy and comparable safety, immunogenicity and PK to the EU-sourced pertuzumab, supporting HLX11 as a potential pertuzumab biosimilar."

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2

Efficacy and safety of perioperative durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma in Asia: A subgroup analysis of the MATTERHORN trial (ESMO Asia 2025) - P3 | "Consistent with global MATTERHORN results, D + FLOT improved efficacy vs P + FLOT with a manageable safety profile in Asian pts with resectable G/GEJ adenocarcinoma."

Clinical • Gastroesophageal Junction Adenocarcinoma • Oncology

Long-Term Disease Control with Combined Immunotherapy and Oral Chemotherapy in Primary Intraosseous Adenoid Cystic Carcinoma of the Mandible with Initial Pulmonary Metastasis (ESMO Asia 2025) - "Two cycles of docetaxel + sintilimab followed, but severe nausea/vomiting led to discontinuation of intravenous chemotherapy. Oral fluoropyrimidines (S-1, capecitabine) are favorable for maintenance due to low toxicity. ACC, an immunologically "cold" tumor, typically responds poorly to immunotherapy, but combined sintilimab and oral capecitabine here enabled prolonged control, suggesting potential for advanced PIACC."

Adenoid Cystic Carcinoma • Oncology

Triple-negative breast cancer with somatic BRCA1 mutation and metaplastic progression in a young woman: A case report (ESMO Asia 2025) - "She underwent modified radical mastectomy with sentinel lymph node biopsy, followed by adjuvant doxorubicin–cyclophosphamide (AC) for 4 cycles, which was complicated by pneumonitis and heart failure. Weekly paclitaxel for 11 cycles was discontinued due to fatigue and elevated troponin, despite a normal ECG...She received gemcitabine–cisplatin for 2 cycles with stable disease, followed by cytoreductive palliative surgery with reconstruction, and then 2 additional cycles of gemcitabine–cisplatin...She was treated with docetaxel–capecitabine for 1 cycle with poor response, followed by sacituzumab govitecan for 3 cycles, which resulted in disease progression. Currently, the patient is on eribulin plus durvalumab, having completed 1 cycle...This case illustrates an unusual histological evolution from medullary carcinoma to metaplastic carcinoma, and subsequently to mucoepidermoid carcinoma. It raises important questions about the optimal timing of genomic testing and the..."

Case report • Clinical • IO biomarker • Tumor mutational burden • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer • BRCA • BRCA1 • HER-2 • PD-L1 • PGR • PTEN • RB1 • SF3B1 • STK11 • TMB • TP53

Pembrolizumab (Pembro) monotherapy for locally advanced or metastatic non–small-cell lung cancer (NSCLC): 10-year outcomes from clinical trials (ESMO Asia 2025) - P1, P2/3, P3 | "Pts received pembro 2 mg/kg Q3W or 10 mg/kg Q2W or Q3W in KN001, and were randomized to pembro 200 mg Q3W vs docetaxel chemotherapy (chemo) in KN010, and platinum-based chemo in KN024 and KN042. With 10 years of follow-up, pembro monotherapy continued to improve survival vs chemo. Limited additional deaths are noted since previously reported 5-year data."

Clinical • Metastases • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Glumetinib plus albumin-bound docetaxel (HB1801) in patients with MET overexpression, actionable genetic alteration- (AGA-) negative non-small cell lung cancer (Gleam Study) (ESMO Asia 2025) - P2 | "Glumetinib plus HB1801 exhibits a tolerable safety profile and a promising efficacy in MET overexpressed, AGA-negative, locally advanced or metastatic NSCLC."

Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced oesophageal squamous cell carcinoma: 3-year follow-up from the phase II trial (ESMO Asia 2025) - P=N/A | "Here we report results with 3-year follow-up. Eligible patients with clinical stage T2-4aN0M0, T1-4aN+M0 OSCC were screened and enrolled, treated with regimen of docetaxel (75mg/m2, days 1), carboplatin (AUC=5-6, day 1), camrelizumab (200 mg, day 1) of two 21-day cycles and underwent surgery within 4–6 weeks after neoadjuvant therapy. After a median follow-up of 3-year, neoadjuvant camrelizumab plus chemotherapy continued to demonstrate clinically meaningful improvements in DFS and OS among patients with locally advanced OSCC. ypN0 is associated with lower recurrence. Long-term results from randomized controlled trials are needed."

Clinical • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Oral Cancer • Squamous Cell Carcinoma

Prospective trial of optimization induction chemotherapy in treatment HPV-positive oropharyngeal squamous cell carcinoma (ESMO Asia 2025) - "A single TPF regimen (cisplatin + docetaxel + 5-fluorouracil), which is highly toxic, was approved as IC...After completion IC patients of both groups had a standard CRT 70 Gy with carboplatin AUC 2.0 weekly... The research regimen of IC demonstrated high results of an objective response, 3-years OS and PFS, comparable to the standard TPF scheme, against the background of better tolerance. In the future, TP can become an alternative regimen of IC in the treatment of HPV-positive squamous cell carcinoma of the oropharynx."

Clinical • Oncology • Oropharyngeal Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

NACT with DCF plus low-dose nivolumab in locally advanced technically unresectable oral cavity cancer: A single-centre study from eastern India (ESMO Asia 2025) - "Patients received NACT with Nivolumab 40 mg + DCF (Docetaxel, Cisplatin, and 5-Fluorouracil) 3 weekly. Low-dose Nivolumab combined with DCF as neoadjuvant therapy was well tolerated and demonstrated encouraging response and resectability rates in technically unresectable OSCCC. This may result in survival benefits in both the surgical and nonsurgical groups."

Clinical • Metastases • Oncology • Oral Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Darolutamide combined with androgen deprivation therapy and prostate arterial docetaxel infusion for locally advanced or oligometastatic hormone-sensitive prostate cancer: A Trial in Progress(DAPLOM Study) (ESMO Asia 2025) - P2 | "With a historical pCR+MRD rate of 5% and a target of 40%, 60 patients yield 80% power (one-sided α = 0.05). Screening/enrollment: Q2–Q4 2025; neoadjuvant therapy complete by Q1 2026; surgery in Q2 2026; final analyses by Q4 2026."

Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • AR

Efficacy and safety of darolutamide-based doublet and triplet therapies in metastatic hormone-sensitive prostate cancer a retrospective study (ESMO Asia 2025) - "Background: Darolutamide is the only next-generation androgen receptor inhibitor (ARi) approved for both doublet (ADT + ARi) and triplet (ADT + ARi + docetaxel) therapy in metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide-based doublet and triplet therapies demonstrated promising efficacy and tolerability in treating mHSPC. Notably, this is the first real-world study in China evaluating both treatment strategies. These findings support their clinical utility and warrant further validation in larger prospective studies."

Metastases • Retrospective data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Immunotherapy in neuroendocrine prostate carcinoma: Can we mirror the small cell lung cancer approach? Real-world outcomes with immune checkpoint inhibitors (ESMO Asia 2025) - "Atezolizumab was combined with carboplatin plus etoposide in 6 patients and with docetaxel plus carboplatin in 5 patients. While ICIs have transformed the management of extensive-stage SCLC by extending survival beyond chemotherapy alone, their application in NEPC has yielded encouraging outcomes. Some patients derive meaningful clinical benefit, though confirmation in larger studies is warranted."

Checkpoint inhibition • Clinical • IO biomarker • Real-world • Real-world evidence • Genito-urinary Cancer • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • BRCA2 • EGFR • FGFR • KMT2D • MLH1 • MYC • NF1 • PDGFRB • PIK3CA • PTEN • RB1 • SYP • TP53

Preoperative ADT combined with docetaxel for conversion therapy in large-volume and unresectable locally advanced or oligometastatic prostate cancer: A multi-center retrospective study (YHCG-001 Study) (ESMO Asia 2025) - P=N/A | "This study suggests that preoperative A+D therapy followed by RP can be offered as multimodal therapy for large-volume and unresectable LAPC and OMPC."

Metastases • Retrospective data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A real-world study of darolutamide combined with docetaxel in patients with metastatic hormone-sensitive prostate cancer in Hainan, China (ESMO Asia 2025) - "Hainan-based prostate cancer pts exhibit more severe metastatic baseline conditions and higher PSA levels compared to darolutamide triplet studies. Docetaxel combined with darolutamide and ADT achieved rapid PSA response, suggesting favorable outcome. The treatment is well-tolerated, allowing for dose adjustments based on individual circumstances."

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), real-world adoption of combination therapies in Australia and Asia (ESMO Asia 2025) - "Background: The addition of androgen receptor pathway inhibitors (ARPI) with or without docetaxel (DOC) to androgen deprivation therapy (ADT) has significantly improved outcomes in mHSPC...In Asia, the most common ARPI was apalutamide (41%) and abiraterone (41%). In Australia, darolutamide (30%) and enzalutamide (30%) were most used... Our real-world data demonstrates improved adoption of standard of care therapy since January 2023 in Australia and Asia. The use of ADT alone may reflect differences in the real-world population. However, the improvement seen in time to CRPC with combination therapy demonstrates the survival gains that can be achieved in the real-world setting."

Clinical • Combination therapy • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Darolutamide-based triple therapy combined with PSMA PET/CT-guided focal treatment in patients with prostate cancer: A Multicenter retrospective study (ESMO Asia 2025) - "Background: Darolutamide, a novel androgen receptor inhibitor, improved survival in mHSPC when combined with ADT and docetaxel in the ARASENS trial. In mHSPC patients, darolutamide-based triple therapy combined with PSMA PET/CT-guided focal treatment achieved high disease control rates with favorable safety, highlighting the advantages of a multimodal precision treatment approach. These findings warrant further validation in prospective studies."

Retrospective data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy and safety of Darolutamide combined with trans-arterial chemoperfusion by Docetaxel in metastatic hormone-sensitive prostate cancer (ESMO Asia 2025) - "In this pilot cohort, the combination regimen of trans-arterial docetaxel chemoperfusionwith darolutamide and ADT demonstrated rapid and profound PSA suppression, significant improvements in voiding parameters, and a manageable safety profile in patients with mHSPC."

Clinical • Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Real-world treatment patterns and safety of olaparib in Chinese patients with prostate cancer: A multicenter, prospective, real-world study (DIM study) (ESMO Asia 2025) - P | "54 (90%) pts had NHA exposure while 27 (45%) had docetaxel exposure before initiating olaparib. This real-world analysis indicates that a considerable proportion of prostate cancer pts are receiving several lines of therapy prior to olaparib. Olaparib was well tolerated in real-world clinical practice in China and its safety profile was consistent with previous reports."

Clinical • HEOR • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Prostate Cancer • Solid Tumor • BRCA

Neoadjuvant Adebrelimab plus SOX and Nab-paclitaxel in Resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase II trial (ESMO Asia 2025) - P2, P3 | "Background: Perioperative chemotherapy containing fluorouracil, oxaliplatin, and docetaxel is preferred for patients with gastric and gastroesophageal junction adenocarcinoma. The KEYNOTE-585 study reported that the neoadjuvant and adjuvant pembrolizumab plus cisplatin-based chemotherapy group achieved a higher pathological complete response rate than the placebo plus cisplatin-based chemotherapy group...The primary endpoint is the pathological complete response rate. Secondary research endpoints include: major pathologic response, objective response rate, R0 resection rate, disease-free survival, overall survival, and safety."

Clinical • Metastases • P2 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor